Last reviewed · How we verify
LVGN7409
At a glance
| Generic name | LVGN7409 |
|---|---|
| Sponsor | Lyvgen Biopharma Holdings Limited |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors (PHASE1)
- CD40 Agonist and PD-1 Inhibitor in HNSCC (PHASE1)
- Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy (PHASE1)
- Study of LVGN7409 (CD40 Agonist Antibody) in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LVGN7409 CI brief — competitive landscape report
- LVGN7409 updates RSS · CI watch RSS
- Lyvgen Biopharma Holdings Limited portfolio CI